A5038835998- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease and Transplantation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Advanced Radiotherapy Techniques
- MRI in cancer diagnosis
- Cancer, Hypoxia, and Metabolism
- Organ Transplantation Techniques and Outcomes
- Ferroptosis and cancer prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Liver Diseases and Immunity
- Liver physiology and pathology
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Folate and B Vitamins Research
- Viral-associated cancers and disorders
- Alcohol Consumption and Health Effects
Ulsan College
2016-2025
University of Ulsan
2016-2025
Asan Medical Center
2016-2025
Korean Cancer Study Group
2022-2024
Hanyang University Guri Hospital
2016-2022
Korea University
2006-2021
Sejong University
2021
Guangxi Medical University
2018
National Cancer Centre Singapore
2018
University Gastroenterology
2013-2018
Hepatic resection is the most curative treatment option for early-stage hepatocellular carcinoma, but associated with a high recurrence rate, which exceeds 50% at 5 years after surgery. Understanding genetic basis of carcinoma surgically curable stages may enable identification new molecular biomarkers that accurately identify patients in need additional early therapeutic interventions. Whole exome sequencing and copy number analysis was performed on 231 carcinomas (72% hepatitis B viral...
<h3>Objective</h3> Little is known about the long-term clinical outcome and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy in patients with chronic hepatitis B (CHB). <h3>Design</h3> During a median follow-up period 6 years (33 567 patient-years) 5409 CHB who were initially treated lamivudine or entecavir, total 110 achieved (0.33% annual rate) included this study. <h3>Results</h3> Baseline alanine aminotransferase (ALT) level >5 times upper limit normal...
OBJECTIVES: The goal of the study was to determine whether endoscopic ultrasound (EUS)-guided biliary drainage (EUS-BD) is comparable conventional transpapillary stenting with retrograde cholangiopancreatography (ERCP) in palliation malignant distal obstruction. Although ERCP for obstruction standard care, post-procedure pancreatitis and stent dysfunctions are not uncommon. While EUS-BD has garnered interest as a viable alternative when impossible, its role primary yet be proven. METHODS: We...
Purpose To identify differences in radiologic assessment methods and determine optimal imaging criteria for response evaluation hepatocellular carcinoma (HCC) patients treated with chemoembolization. Materials Methods Institutional review board approval was obtained, patient informed consent waived. The present study included 332 intermediate stage HCC Child-Pugh A cirrhosis who underwent serial All measurable target lesions of 1 cm or larger diameter were uni- bidimensionally measured both...
Objective High serum HBV DNA levels are associated with high risks of hepatocellular carcinoma (HCC) and cirrhosis in patients chronic hepatitis B (CHB). Although the immune-tolerant (IT) phase is characterised by circulating levels, it remains unknown whether antiviral treatment reduces HCC mortality. Design This historical cohort study included HBeAg-positive CHB (≥20 000 IU/mL) no evidence at a tertiary referral hospital Korea from 2000 to 2013. The clinical outcomes 413 untreated...
In Brief Objective: To develop clinical predictive nomograms generating per-patient numerical probabilities of postoperative recurrence-free and overall survival at specific times. Background: The prognosis after surgical resection is diverse in patients with early-stage hepatocellular carcinoma (HCC). Methods: a retrospective review, we evaluated data from 1085 mostly newly diagnosed HCC who were subsequently treated by curative resection. We randomly divided the subjects into derivation (n...
ABSTRACT Background and Aims Real‐world data on the variceal bleeding (VB) risk in patients receiving atezolizumab–bevacizumab (Atezo–Bev) treatment remain limited. This study aimed to assess of VB identify factors with advanced hepatocellular carcinoma (HCC) Atezo–Bev treatment. Methods retrospective included 640 HCC who underwent endoscopy before at two hospitals Korea. The primary outcome was occurrence VB, non‐VB events considered as competing events. Results Of patients, mean age 61.3...
We prospectively investigated the association between a change of serum vascular endothelial growth factor (VEGF) level after transcatheter arterial chemoembolization (TACE) and hepatocellular carcinoma (HCC) patient prognosis. The study involved 147 patients with unresectable HCC treated at National Cancer Center, Korea, July December 2005. Serum samples were collected from each before TACE, 1–2 days 1 month TACE. VEGF concentrations measured using an enzyme‐linked immunosorbent assay...
A recent study in young Italian subjects suggested that the healthy thresholds for serum alanine aminotransferase (ALT) levels should be adjusted to 30 IU/L men and 19 women when assessing risk factors nonalcoholic fatty liver disease. Our aim was assess ALT concentrations Korean individuals determine affecting these populations. We included 1,105 potential donors (643 462 women) with biopsy-proven normal livers. Median ages were 25 years women, a median body mass index (BMI) of 22.3 kg/m2...
BackgroundEven with early stage hepatocellular carcinoma (HCC), patients are often ineligible for surgical resection, transplantation, or local ablation due to advanced cirrhosis, donor shortage, difficult location. Stereotactic body radiation therapy (SBRT) has been established as a standard treatment option I lung cancer, who not eligible surgery, and may be promising alternative small HCC curative treatment. Materials MethodsA registry database of 93 were treated SBRT between 2007 2009...
Background & AimsLittle is known about whether the antiviral agent entecavir more effective than a less potent drug, lamivudine, in reducing risk of death and hepatocellular carcinoma (HCC) patients with chronic hepatitis B.MethodsWe performed retrospective analysis data from 5374 consecutive adult B, treated (n = 2000) or lamivudine 3374), at tertiary referral hospital Seoul, Korea, November 1, 1999, through December 31, 2011. Data were collected for up to 6 years analyzed by multivariable...
To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined transarterial chemoembolization (TACE) versus monotherapy.The retrospective analysis of data was approved by institutional review board, requirement obtain informed consent waived. Of 355 HCC (Barcelona Clinic Liver Cancer stage C) were therapy for at least 5 weeks between April 2007 July 2011, 164 (46.2%) underwent...
There is conflict regarding the prevalence of coronary artery disease (CAD) in patients with liver cirrhosis. This study aimed to investigate silent CAD comparison general population, and identify relevant risk factors cirrhosis.This retrospective included 1045 prospectively registered consecutive cirrhosis without any history chest pain or CAD, who underwent computerized angiography as a pretransplant workup. These were matched 6283 controls healthy livers, based on propensity scores...
Atezolizumab-bevacizumab is the new standard of care for first-line treatment advanced hepatocellular carcinoma (HCC). However, optimal sequence therapy after disease progression on atezolizumab-bevacizumab unclear.This multinational, multicenter, and retrospective study assessed clinical outcomes patients with HCC who received subsequent systemic between July 2016 April 2019.Among 71 treated atezolizumab-bevacizumab, a total 49 were included in this analysis; median age was 60 years (range,...
Background/Aims: Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy SBRT small (≤5 cm) HCCs.Methods: A phase II, single-arm clinical trial on HCCs conducted at academic tertiary care center. planned dose 45 Gy a fraction size 15-Gy over 3 consecutive days. primary endpoint 2-year local control...
Abstract Background and Aims: The therapeutic efficacy of transarterial chemoembolization (TACE) has not been evaluated in hepatocellular carcinoma (HCC) patients with extrahepatic metastasis. We investigated the TACE with/without systemic chemotherapy (s‐chemo) these patients. Methods: performed a survival analysis consecutive HCC metastasis, diagnosed at initial presentation according to treatment modality after stratification, using Child–Pugh classification intrahepatic T stage,...
We evaluated efficacy of exercise and diet modification for steatosis improvement non-obese non-alcoholic fatty liver disease (NAFLD) patients.We analyzed retrospectively the clinical histological parameters consecutive living donors, who experienced repeated biopsies due to were treated using modification.From 1995 2009, among a total 1365 potential donors with NAFLD seen on initial biopsy, 120 ≥ 30% or an estimated donor-recipient weight ratio < 0.8, underwent received follow-up biopsy at...
Abstract Background & Aim The need for a subclassification of Barcelona Clinic Liver Cancer ( BCLC ) intermediate‐stage B) has arisen because its diversity. We evaluated the prognostic capability B proposed by Bolondi et al. in patients treated with transarterial chemoembolization TACE ). Furthermore, we introduce new hepatocellular carcinoma HCC using parameter related to tumour burden (up‐to‐11 criteria). Methods Of 3268 as first‐line treatment, 821 were included this study. Results...
We aimed to generate and validate a novel risk prediction model for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).Patients receiving TACE as the first-line therapy between 2006 2009 were selected from databases of two major tertiary hospitals in Korea. This study population was randomly assigned into training (n = 340) validation 145) sets. From multivariate Cox-regression overall survival (OS), tumour Size, Number, baseline Alpha-foetoprotein...